DexCom Net Worth
DexCom Net Worth Breakdown | DXCM |
DexCom Net Worth Analysis
DexCom's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including DexCom's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of DexCom's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform DexCom's net worth analysis. One common approach is to calculate DexCom's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares DexCom's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing DexCom's net worth. This approach calculates the present value of DexCom's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of DexCom's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate DexCom's net worth. This involves comparing DexCom's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into DexCom's net worth relative to its peers.
Enterprise Value |
|
To determine if DexCom is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding DexCom's net worth research are outlined below:
| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: DexCom to invest 75M in smart ring firm URA |
DexCom uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in DexCom Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DexCom's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know DexCom's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DexCom is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DexCom Inc backward and forwards among themselves. DexCom's institutional investor refers to the entity that pools money to purchase DexCom's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main | 6.7 M | Nuveen Asset Management, Llc | 2024-06-30 | 6.4 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 6.3 M | Amvescap Plc. | 2024-06-30 | 6.2 M | Artisan Partners Limited Partnership | 2024-06-30 | 5.6 M | Norges Bank | 2024-06-30 | 5.4 M | Wellington Management Company Llp | 2024-06-30 | 5.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 4.4 M | Blair William & Co | 2024-06-30 | 4.3 M | Vanguard Group Inc | 2024-09-30 | 47.4 M | Blackrock Inc | 2024-06-30 | 34.5 M |
Follow DexCom's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 29.39 B.Market Cap |
|
Project DexCom's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.09 | |
| Return On Capital Employed | 0.13 | 0.13 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.26 | 0.27 |
When accessing DexCom's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures DexCom's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of DexCom's profitability and make more informed investment decisions.
Evaluate DexCom's management efficiency
DexCom Inc has return on total asset (ROA) of 0.0606 % which means that it generated a profit of $0.0606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3206 %, meaning that it created $0.3206 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.13. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 22nd of November 2024, Intangible Assets is likely to grow to about 141.2 M, while Debt To Assets are likely to drop 0.37.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.36 | 5.63 | |
| Tangible Book Value Per Share | 4.95 | 5.19 | |
| Enterprise Value Over EBITDA | 54.46 | 57.19 | |
| Price Book Value Ratio | 23.16 | 24.31 | |
| Enterprise Value Multiple | 54.46 | 57.19 | |
| Price Fair Value | 23.16 | 24.31 | |
| Enterprise Value | 220.9 M | 231.9 M |
DexCom showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 7.422 | Revenue 4 B | Quarterly Revenue Growth 0.02 | Revenue Per Share 10.089 | Return On Equity 0.3206 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DexCom insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Altman Steven R over six months ago Acquisition by Altman Steven R of 2613 shares of DexCom subject to Rule 16b-3 | ||
Jacob Leach over six months ago Disposition of 2932 shares by Jacob Leach of DexCom at 121.8505 subject to Rule 16b-3 | ||
Altman Steven R over six months ago Disposition of 2885 shares by Altman Steven R of DexCom subject to Rule 16b-3 | ||
Matthew Dolan over six months ago Disposition of 2423 shares by Matthew Dolan of DexCom at 126.58 subject to Rule 16b-3 | ||
Matthew Dolan over six months ago Disposition of 1003 shares by Matthew Dolan of DexCom at 131.3912 subject to Rule 16b-3 | ||
Yang Richard over a year ago DexCom exotic insider transaction detected | ||
Jorge Valdes over a year ago Exercise or conversion by Jorge Valdes of 10000 shares of DexCom subject to Rule 16b-3 |
DexCom Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of May 2024 Other Reports | ViewVerify | |
| 22nd of April 2024 Other Reports | ViewVerify |
DexCom Earnings per Share Projection vs Actual
DexCom Corporate Management
| Shelly Selvaraj | Senior Officer | Profile | |
| Leverne Marsh | Executive Marketing | Profile | |
| Matthew Dolan | Corporate Strategy | Profile | |
| Teri Lawver | Executive Officer | Profile | |
| Donald Abbey | Quality Services | Profile | |
| Jereme Sylvain | CFO VP | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.